Clinical Report: Optimizing Polycythemia Vera Management Through a Collaborative Care Model

Background

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by increased blood viscosity and thrombotic risk due to JAK2 mutations. Effective management is crucial to minimize complications and improve patient quality of life. Variability in treatment practices highlights the need for standardized care approaches, particularly in multidisciplinary settings.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Pharmacists can bridge care gaps in PV management through proactive interventions.
• The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-10) is underutilized in assessing symptom burden.
• A pharmacist-led hydroxyurea management program improved hematocrit control in PV patients.
• Collaborative practice agreements allow pharmacists to perform medication management and adjust therapy under physician oversight.
• The initiative aims to standardize care across a large health network.

Clinical Implications

The pharmacist-driven program can enhance adherence to therapy and optimize treatment selection for PV patients. Regular symptom assessments and proactive management strategies are essential for improving patient care and outcomes.

Conclusion

Implementing a collaborative care model involving pharmacists can significantly enhance the management of polycythemia vera, addressing gaps in treatment and improving patient outcomes.

Related Resources & Content

1. Iurlo et al., 2020 -- Polycythemia Vera Management
2. Tefferi et al., 2021 -- Polycythemia Vera Overview
3. Marchioli et al., 2011 -- Therapy Goals in PV
4. Gerds et al., 2022 -- MPN-10 Assessment Tool
5. Andrick et al., 2020 -- PERMANACE Study
6. Chojecki et al., 2022 -- Pharmacist Collaboration in MF Care
7. The ASCO Post — Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
8. Bone Marrow Transplantation — The 51st Annual Conference of the European Society for Blood and Marrow Transplantation: Pharmacists' Committee – Poster Presentations (P919-P930)
9. the asco post — Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera
10. The ASCO Post — Prognostic Models and Front-Line Treatment Options for Chronic-Phase Chronic Myelogenous Leukemia
11. Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera
12. Diagnosis and Treatment of Polycythemia Vera: A Review | Oncology | JAMA
13. Polycythemia Vera - Hematology - Merck Manual Professional Edition
14. Version 2.2025
15. Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study - ScienceDirect
16. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera | New England Journal of Medicine
17. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study - PMC
18. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b - PMC
19. Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV) - PubMed
20. Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV). | Journal of Clinical Oncology